In the latest quarter, 4 analysts provided ratings for LeMaitre Vascular (NASDAQ:LMAT), showcasing a mix of bullish and bearish perspectives.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for LeMaitre Vascular, presenting an average target of $106.0, a high estimate of $118.00, and a low estimate of $94.00. Surpassing the previous average price target of $100.75, the current average has increased by 5.21%.

Deciphering Analyst Ratings: An In-Depth Analysis

The standing of LeMaitre Vascular among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to LeMaitre Vascular. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of LeMaitre Vascular compared to the broader market.
• Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.

Capture valuable insights into LeMaitre Vascular's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on LeMaitre Vascular analyst ratings.

About LeMaitre Vascular

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.

LeMaitre Vascular: Financial Performance Dissected

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: Over the 3M period, LeMaitre Vascular showcased positive performance, achieving a revenue growth rate of 11.36% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: LeMaitre Vascular's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 28.44%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): LeMaitre Vascular's ROE excels beyond industry benchmarks, reaching 4.68%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): LeMaitre Vascular's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.95% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: LeMaitre Vascular's debt-to-equity ratio is below the industry average. With a ratio of 0.49, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

Analyst Ratings: What Are They?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.